Dapagliflozin - new solution in chronic kidney disease treatment

• Published in: Prospects in Pharmaceutical Sciences Vol. 22; no. 2; pp. 59 - 64
• Main Authors: Bara, Maciej, Starownik, Jakub, Szydło, Jakub, Gryszkiewicz, Patryk, Nieznański, Jakub
• Format: Journal Article
• Language: English; Polish
• Published: 05-06-2024
• ISSN: 2957-0468; 2957-0468
• DOI: 10.56782/pps.195

Despite being developed relatively recently, SGLT2 inhibitors have proven to be versatile pharmaceuticals useful in treatment of diabetes mellitus, heart failure and chronic kidney disease. Extensive and ongoing studies confirm more and more of their beneficial effects on metabolic, cardiovascular and renal health. Most of the conducted studies focused on patients suffering from diabetes mellitus type 2. Recent study, DAPA - CKD, published in the New England Journal of Medicine confirmed dapagliflozin’s beneficial effect on chronic kidney disease of any etiology. This discovery has cemented flozins’ status as nephroprotective drugs and led to a new indication of use for dapagliflozin - chronic kidney disease. In Poland treatment of chronic kidney disease with dapagliflozin is reimbursed in patients with chronic kidney disease with eGFR <60 ml/min/1.73m2, albuminuria or proteinuria who were treated with ACEi/ARB for ≥4 weeks or with contraindications for ACEi/ARB therapy. Due to reimbursement, dapagliflozin therapy is financially available for a wide population of patients and, in light of recent discoveries, should be considered by clinicians.